[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myocardial-infarction":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,42,74,104,136,159,186,225,250,270,290,311,336,363,384,411,436,466,502,527,548,572,604,621,639],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100444898","arrhythmia-detection-after-mi-100444898",false,"NCT05073419","Arrhythmia Detection After MI","Arrhythmia Detection After Myocardial Infarction Trial","AID MI","Inclusion Criteria:\n\n* Adults, age 18 years or older\n* AMI (STEMI and NSTEMI)\n* Willing to give written informed consent\n* Expected discharge from hospital within 7 days of AMI\n* Willing to receive ICM insertion within 21 days of index AMI\n\nExclusion Criteria:\n\n* Existing pacemaker, ICD, ICM, or any other implantable cardiac electronic device\n* Pregnant\n* Index AMI was more than 21 days\n* Unwilling\u002Fcannot insert ICM within 21 days post AMI\n* Planned ICD implant, planned CABG or any open-heart surgery (e.g. for severe valvular disease)","ALL","18 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Patients post acute myocardial infarction (AMI) have a high risk of mortality but the use of an implantable defibrillator in the early aftermath of an AMI has not been shown to improve patients' survival. The VEST trial recently demonstrated an improved overall survival in post AMI patients with the use of a wearable defibrillator. The same improvement was not demonstrated for the risk of sudden cardiac death. Monitoring patients after AMI using an implantable cardiac monitor (ICM) may document findings that can impact patient management and eventually improve their outcomes. We are therefore conducting the AID MI trial to examine the impact of ICM on patient management in the post AMI setting.",[28],"Acute Myocardial Infarction","RECRUITING","2026-06-03",{"date":32,"type":33},"2026-06-05","ACTUAL",{"date":35,"type":33},"2022-08-09",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"Samir Saba","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100634216","phase-4-adenosine-pre-medication-in-primary-percutaneous-coronary-intervention-100634216","NCT07536802","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial","AMPACT","Inclusion Criteria:\n\n* All patients with acute STEMI undergoing primary PCI\n* Patients of either sex, ≥18 years of age.\n\nExclusion Criteria:\n\n* STEMI patients with cardiogenic shock at presentation\n* Patients with heart block\n* Allergy to adenosine\n* Patients refuse to give consent for participation","80 Years",{"count":52,"type":22},1148,[54],"PHASE4","Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow\u002Fno-reflow after primary percutaneous coronary intervention.",[57,58,59,28],"ST-Segment Elevation Myocardial Infarction (STEMI)","No-Reflow Phenomenon","Coronary Slow Flow",[61,62,57,58,59,63],"Adenonsine","Primary Percutaneous Coronary Intervention (Primary PCI)","Myocardial Reperfusion","2026-04-17",{"date":66,"type":33},"2026-04-22",{"date":68,"type":33},"2025-06-01",{"date":70,"type":22},"2026-12-31",{"name":72,"class":40},"National Institute of Cardiovascular Diseases, Pakistan",2,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100541934","phase-4-effect-of-influenza-vaccination-after-myocardial-infarction-on-cardiac-inflammatory-response-100541934","NCT06336317","Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE - a Randomized, Double-blind, Placebo-controlled, Trial (ELIMINATE Trial)","ELIMINATE","Inclusion Criteria:\n\n* Patients with a diagnosis of non-ST-segment elevation myocardial infarction\n* A finalized coronary PCI\n* Male or non-fertile female subjects ≥18 years. (Females without childbearing potential, postmenopausal women and women with a history of hysterectomy or other medical conditions that preclude pregnancy)\n* Written informed consent\n* A CCTA can be scheduled within 7 days after PCI\n\nExclusion Criteria:\n\n* Has received influenza vaccination within 6 months\n* Other vaccination planned within 8 weeks (including covid-19 booster doses)\n* Severe allergy to eggs or previous allergic reaction to influenza vaccine\n* Cardiac surgery or staged PCI planned within 8 weeks\n* Coronary stent involving the proximal RCA\n* Suspicion of febrile illness or acute, ongoing infection\n* Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol\n* Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response\n* Inability to provide informed consent\n* Previous randomization in the ELIMINATE trial\n* Any non-cardiovascular condition, e.g. malignancy, with a life expectancy of less than 1 year based on the investigator´s clinical judgement.\n* Contraindication to coronary CT angiography (e.g., inability to lie flat, contraindication to glyceryl trinitrate, previous contrast allergy or contrast-induced nephropathy, severe renal impairment \\[eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\\])\n* Atrial fibrillation\n* Uncontrolled chronic inflammatory disease\n* Unable to comply with protocol requirements",{"count":83,"type":22},90,[54],"The goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary objective is to compare the effects of influenza vaccination to those of a placebo in reducing post-myocardial infarction coronary inflammation as measured by coronary computed tomography angiography (CCTA). The main questions it aims to answer are:\n\nDoes influenza vaccination reduce arterial inflammation as measured by CCTA at week 8 after percutaneous coronary intervention (PCI) in comparison to baseline? Does influenza vaccination modulate systemic inflammation as measured by blood biomarkers and in-vitro challenge tests at week 8 after PCI in comparison to baseline? Researchers will compare the effects of influenza vaccination with those of a placebo.",[28,87,88],"Cardiovascular Diseases","Inflammatory Response",[90,91,92,93],"Coronary computed tomography angiography","Percutaneous coronary intervention","Influenza vaccine","Non ST-segment elevation myocardial infarction","2026-04-01",{"date":96,"type":33},"2026-04-07",{"date":98,"type":33},"2024-04-24",{"date":100,"type":22},"2027-12",{"name":102,"class":40},"Region Örebro County",3,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":41},"100630812","subdima-subclinical-depression-in-acute-myocardial-infarction-subdima25-100630812","NCT07492537","SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25)","SUBDIMA Study: Subclinical Depression in Myocardial Infarction -Prevalence, Predictors and Prognostic Impact.","SUBDIMA25","Inclusion Criteria:\n\n* Age ≥18 years\n* Hospital admission for first acute myocardial infarction (STEMI or NSTEMI) within 7 days from the index event\n* PHQ-9 administered at screening\n* Mini Mental State Examination (MMSE) score ≥26\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Previous history of acute myocardial infarction\n* Diagnosis of major depression according to DSM-5 TR criteria\n* Severe cognitive impairment (MMSE \\\u003C26)\n* Severe comorbidities with expected survival \\\u003C12 months\n* Inability to participate in scheduled follow-up assessments\n* Refusal or inability to provide informed consent\n* Concurrent participation in other interventional clinical studies that could interfere with study outcomes",{"count":113,"type":22},100,[25],"This is an exploratory, prospective, non-profit study (SUBDIMA) designed to investigate the prevalence and potential prognostic significance of subclinical depression in patients admitted with a first acute myocardial infarction (AMI). Subclinical depression refers to the presence of mild depressive symptoms (PHQ-9 score 5-9) that do not meet DSM-5 TR criteria for major depressive disorder but may still be clinically relevant. The primary aim is to estimate the prevalence of subclinical depression in this setting. Secondary, exploratory objectives include evaluating associations with inflammatory and metabolic biomarkers, autonomic dysfunction, cardiac function, cognitive performance, quality of life, treatment adherence, and the risk of recurrent cardiovascular events over 12 months. The study is expected to generate new descriptive data that may inform future confirmatory trials and support early, personalized approaches to integrated cardiac and mental health care.",[28,117],"Subclinical Depression",[119,120,121,122,123,124,125,28,117,126],"Depression","Mental Health","Cardiovascular Outcomes","Quality of Life","Biomarkers","Autonomic Dysfunction","Cognitive Function","PHQ-9","2026-03-19",{"date":129,"type":33},"2026-03-25",{"date":131,"type":33},"2025-10-14",{"date":133,"type":22},"2027-10",{"name":135,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":145,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":103},"100453511","multi-center-collaborative-to-enhance-quality-and-outcomes-in-the-management-of-cardiogenic-shock-100453511","NCT05185492","Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock","VANQUISH SHOCK","Inclusion Criteria:\n\n* Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes\n* Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry\n\nExclusion Criteria:\n\n* Patients with shock not due to primary cardiac etiology will be excluded. These include septic, hemorrhagic, and anaphylactic shock.",{"count":144,"type":22},500,"1 Year","OBSERVATIONAL","This large real-world international prospective registry will provide a unique opportunity to comprehensively understand the contemporary management, clinical course and short as well as long-term outcomes of all Cardiogenic Shock (CS) patients cared for at four high volume dedicated shock care centers. As the first true North American multicenter CS collaborative with a uniform dedicated and comprehensive case report form, the high patient volumes and wide spectrum of clinical acuity seen at these institutions will provide valuable insight into the factors associated with adverse outcomes; and will serve as a blueprint for future clinical trial designs that may better inform clinical practice.",[149,28],"Cardiogenic Shock","2026-03-18",{"date":152,"type":33},"2026-03-20",{"date":154,"type":33},"2022-05-25",{"date":156,"type":22},"2027-12-31",{"name":158,"class":40},"STAVROS G DRAKOS",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":167,"targetDuration":169,"studyType":146,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100403070","burden-of-new-onset-atrial-fibrillation-in-patients-with-acute-myocardial-infarction-100403070","NCT04528511","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction: the BENEFIT-AMI Multicenter Prospective Registry","BENEFIT-AMI","Inclusion Criteria:\n\n* Adult patients (\\>18 years old);\n* Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization;\n* Patients must have received in-hospital CEM for at least 5 days;\n* Patients must give informed consent.\n\nExclusion Criteria:\n\n* Patients with a medical history of pre-existing AF;\n* Patients with a medical history of rheumatic valvular disease;\n* Patients with a medical history of sick sinus syndrome;\n* Patients undergoing emergent coronary artery bypass surgery;\n* Patients who suffer malignant tumors with an expected lifetime less than 1 year ;\n* Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved;\n* Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI;\n* Patients who have died during the index hospitalization.",{"count":168,"type":22},774,"2 Years","To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.",[172,28],"Atrial Fibrillation New Onset",[28,174,175,176,121],"New-Onset Atrial Fibrillation","Burden","Prospective","2026-03-16",{"date":127,"type":33},{"date":180,"type":33},"2020-10-01",{"date":182,"type":22},"2028-06-30",{"name":184,"class":40},"Shanghai 10th People's Hospital",5,{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":206,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":73},"100576667","aerobic-exercise-induced-effect-on-endothelial-function-in-patients-with-ischaemic-heart-disease-100576667","NCT06788275","Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease","Effect of Different Aerobic Exercise Methods in Cardiac Rehabilitation on Endothelial Function in Patients With Ischaemic Heart Disease and Study of the Associated Physiological Mechanisms (ENDO-R)","ENDO-R","Inclusion Criteria:\n\n* Men and women aged between 45 and 75 years.\n* Diagnosed with acute myocardial infarction, unstable or stable angina.\n* Treated with percutaneous coronary intervention, coronary artery bypass grafting, or conservative treatment.\n* Event or intervention within 3 to 12 months prior to participation in the study.\n* Fluency in speaking and reading Spanish.\n* Residing in Elche or surrounding areas and able to attend evaluations and the exercise programme (not planning to be absent for more than one week during the programme).\n* Functional Class I-II according to the New York Heart Association (NYHA) classification.\n* No physical limitations for exercise.\n* Stable optimal medical treatment.\n* Physically inactive, defined as 1) not meeting the World Health Organization recommendations for both aerobic and strength exercise, and 2) not participating in a structured exercise programme at least 3 days per week for more than 3 months. Both conditions must be met for inclusion. Note: Casual walking is not considered grounds for exclusion.\n\nExclusion Criteria:\n\n* Use of walking assistive devices.\n* Treatment with chemotherapy for any type of cancer in the past 2 years.\n* Hospitalisation in an intensive care unit in the past 6 months for reasons other than the ischaemic event.\n* Acute myocardial infarction group IV Killip-Kimball.\n* Obesity grade III (≥40.0 kg\u002Fm²).\n* Medical contraindication for inclusion in an exercise programme.\n* Diabetes with uncontrolled blood glucose levels.\n* Poorly controlled hypertension: resting blood pressure \\> 180\u002F110 mmHg.\n* Chest pain with exertion or ST-segment changes suggestive of residual ischemia during ergometry. Residual ischemia.\n* Severely reduced functional capacity on initial ergometry (\\<5 metabolic equivalent of task).\n* Left ventricular ejection fraction less than 50%.\n* Severe stenosis of the left main coronary artery (\\>50% significant disease).\n* Severe aortic stenosis, left ventricular outflow tract obstruction (e.g., obstructive hypertrophic cardiomyopathy) or aortic dissection.\n* Severe valvulopathy.\n* Acute pulmonary embolism or deep vein thrombosis.\n* Severe pulmonary hypertension.\n* Acute heart failure.\n* Acute endocarditis, myocarditis, or pericarditis.\n* Acute or chronic renal insufficiency (estimated glomerular filtration rate \\<30 ml\u002Fmin).\n* Pulmonary fibrosis or interstitial disease (severe respiratory insufficiency or confirmed chronic obstructive pulmonary disease).\n* Uncontrolled cardiac arrhythmias\u002Fhemodynamically unstable.\n* Permanent or persistent\u002Fparoxysmal atrial fibrillation with episodes in the past 6 months.\n* High-grade cardiac block.\n* Presence of implantable devices: cardiac resynchronization therapy pacemaker, implantable cardioverter defibrillators, or pacemaker.\n* Presence of ischaemic symptoms during the incremental exercise test performed before the intervention.\n* Severe autonomic or peripheral neuropathy.\n* Use of nitrates in pharmacological treatment.\n* Any planned surgical or medical intervention during the study period.\n* Plans to participate in or current participation in other studies that may interfere with this study.\n* Current pregnancy or intention to become pregnant during the study period.","45 Years","75 Years",{"count":197,"type":22},132,[25],"Endothelial dysfunction is one of the aetiological factors in ischaemic heart disease (IHD). Aerobic exercise is effective in improving endothelial function, as measured by flow-mediated dilation (FMD), in patients with IHD. Within the aerobic exercise methods, there is evidence showing that high-intensity interval training (HIIT) increases FMD to a greater extent than moderate-intensity training (MIT) in these patients. Notably, in a recent review, our research group found that only studies performing long bouts of HIIT (long HIIT: higher than 1 min) found a greater effect on FMD, while no differences were found in those studies using short bouts of HIIT (short HIIT: ≤ 1 min) and MIT. However, no experimental studies comparing the effect of long HIIT, short HIIT, and MIT on endothelial function, as well as other predictors of mortality, such as cardiorespiratory fitness, brain-derived neurotrophic factor (BDNF) levels or parasympathetic branch activity, have been performed. Therefore, the main objective of this project will be to compare the effect of the three aerobic exercise methods on endothelial function, as measured by FMD, in patients with IHD. Complementarily, the effect of aerobic exercise, depending on the exercise method, on different mortality predictors will be compared. For this purpose, a multicentre randomised study will be carried out (2 hospitals in Elche and one in Alicante). Assessors will be blinded to the patients allocation. Participants will be aware about their allocation in the experimental groups due to the nature of the study. A total of 132 men and women with IHD (66 per sex), diagnosed between three and 12 months before the start of the intervention, aged between 45 and 75 years, and without limitations for the practice of exercise training, will be recruited. All patients will train 3 days a week for 12 weeks. Participants will be assessed before the intervention (i.e., pre), at 6 weeks of training (i.e., mid) and after the intervention (i.e., post). Physiological and psychological variables will be registered in the assessment periods. Training intensity will be individually prescribed based on the cardiopulmonary exercise test (CPET). Intensity exercise will be adapted after the first part of the intervention. Analysis of covariance will be used to compare the values of the three groups after the intervention for the continuous variables, including the pre-intervention value as a covariate, while a logistic regression model will be used for the categorical variables.",[201,28,202,203,204,205],"Percutaneous Coronary Intervention (PCI)","Angina (Stable)","Unstable Angina Pectoris","Cardiorespiratory Fitness","Ischaemic Heart Diseases",[207,208,209,210,211,212,213,214],"Aerobic exercise","High-intensity interval training","Cardiac rehabilitation","Multicenter study","Coronary artery disease","Flow-mediated dilation","Nitroglycerin-mediated dilation","Mortality predictors","2026-02-25",{"date":217,"type":33},"2026-02-27",{"date":219,"type":33},"2024-11-01",{"date":221,"type":22},"2027-11",{"name":223,"class":224},"Instituto de Investigación Sanitaria y Biomédica de Alicante","NETWORK",{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":41},"100624975","impact-of-new-onset-insomnia-after-coronary-revascularization-for-patients-with-acute-myocardial-infarction-100624975","NCT07416617","Impact of New-onset Insomnia After Coronary Revascularization for Patients With Acute Myocardial Infarction","MI-INSOMINA","Inclusion Criteria:\n\n* Diagnosis of acute myocardial infarction\n* Undergoing percutaneous coronary intervention or coronary artery bypass surgery\n\nExclusion Criteria:\n\n* Pre-existing phychiatric disorders",{"count":233,"type":22},235342,"The present study aimed to evaluate the impact of acute insomnia on long-term clinical outcomes in patients underwent PCI or CABG for AMI using the Korean National Health Insurance Service (NHIS) database, and to identify the factors through which insomnia contributes to prognostic determination in this patient population.",[28,236],"Insomina",[238,239],"acute myocardial infarction","insomnia","NOT_YET_RECRUITING","2026-02-10",{"date":243,"type":33},"2026-02-18",{"date":245,"type":22},"2026-02-12",{"date":247,"type":22},"2026-06-30",{"name":249,"class":40},"Samsung Medical Center",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":41},"100623732","long-term-follow-up-study-following-the-approval-of-hearticellgram-ami-administration-100623732","NCT07400458","Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration","Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n1. Those who had administered Hearticellgram-AMI\n2. Those who voluntarily agreed in writing to participate in this investigation\n\nExclusion Criteria:\n\n\\-",{"count":113,"type":22},[25],"This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.",[28],"2026-02-06",{"date":241,"type":33},{"date":264,"type":33},"2022-03-03",{"date":266,"type":22},"2032-09-30",{"name":268,"class":269},"Pharmicell Co., Ltd.","INDUSTRY",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":185},"100461726","phase-4-impact-of-early-pcsk9-inhibitor-treatment-on-heart-after-acute-myocardium-infarction-100461726","NCT05292404","Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction","Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction： a Muti-center, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. The age is greater than 18 years old and less than or equal to 80 years old.\n2. Patients who are clinically diagnosed with STEMI onset within 24 hours and who are planning to undergo PPCI .\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Patients who are allergic to PCSK9 inhibitors.\n2. Multivessel disease planned for selective intervention within half a year.\n3. Patients who have previously undergone revascularization.\n4. Pregnant women or women who plan to become pregnant in the next 2 years.\n5. Patients whose life expectancy is less than 1 year.\n6. Severe liver or kidney dysfunction (ALT\\>5 times ULA, eGFR\\\u003C15ml\u002Fmin\u002F1.73m2)\n7. Known active malignant tumor diseases.\n8. Patients considered by the investigator to be unsuitable to participate in this study.",{"count":278,"type":22},160,[54],"This is a multi-center, prospective, randomized, controlled study. The patients with STEMI who were to undergo PPCI were divided into PCSK9 inhibitor group (n=80) and conventional treatment group (n=80) using the interactive web response system (IWRS), at a 1:1 ratio. In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months; the control group received conventional treatment. Cardiac Magnetic Resonance Imaging (MRI) were used to measure myocardial salvage index at 1 week after operation as primary endpoints. Eject fraction at 6 months after operation will also be measured by MRI as secondary endpoints. Serum TnI\u002FT，CKMB levels were detected q8h for three times and and LDL-C levels were detected at 1 month, 3 months and 6 months after operation. Blood inflammation indicators were detected before and 1 week after the operation, and 6 months after the operation.",[28],"2026-01-23",{"date":284,"type":33},"2026-01-27",{"date":286,"type":33},"2022-10-01",{"date":37,"type":22},{"name":289,"class":40},"Shanghai Tong Ren Hospital",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100615101","the-benefits-of-wearable-ai-in-post-discharge-management-of-ami-patients-100615101","NCT07288229","The Benefits of Wearable AI in Post-Discharge Management of AMI Patients","The Benefits of Wearable Device-Based Artificial Intelligence in Post-Discharge Management of Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Confirmed diagnosis of acute myocardial infarction (AMI), including both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI).\n* Underwent successful percutaneous coronary intervention (PCI) during index hospitalization.\n* Hemodynamically stable at the time of hospital discharge.\n* Willing and able to wear a smartwatch continuously for the study period.\n* Compatible with the data collection application and have stable internet access.\n\nExclusion Criteria:\n\n* Planned staged or elective PCI or any coronary revascularization scheduled within 3 months after discharge.\n* Unable to tolerate or contraindicated for wearing metal or electronic monitoring devices.\n* Pregnant or breastfeeding women.\n* Residence in an area without stable network connectivity or inability to use a smartphone for data upload and communication.\n* Severe comorbidities that limit 3-month survival or follow-up.",{"count":21,"type":22},[25],"Myocardial infarction (MI) remains a major threat to human health. Although interventional treatment techniques have advanced rapidly, many patients still experience major adverse cardiovascular events (MACE) and require hospital readmission after discharge. Artificial intelligence (AI) based on wearable device data has shown great potential in the diagnosis and management of cardiovascular diseases.\n\nThis study aims to explore the clinical value of wearable device-based data analysis and AI-driven risk stratification models in post-discharge management of acute myocardial infarction (AMI) patients.",[28,301],"Heart Failure","2025-12-15",{"date":304,"type":33},"2025-12-17",{"date":306,"type":22},"2025-12-30",{"date":308,"type":22},"2026-12-30",{"name":310,"class":40},"RenJi Hospital",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":103},"100588878","stellate-ganglion-morphine-infiltration-on-myocardial-ischemia-reperfusion-injury-100588878","NCT06947135","Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury","The Effect of Targeted Stellate Ganglion Morphine Infiltration on Reperfusion Injury in STEMI Patients After Primary PCI: A Randomized Controlled Trial","tSGM-AMI","Inclusion Criteria:\n\n1. Aged ≥18 years, Male or Female.\n2. Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW).\n3. Within 24 hours of the onset of infarct-related chest pain.\n4. Obtaining informed consent from the patient and their family.\n\nExclusion Criteria:\n\n1. Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall;\n2. Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs;\n3. Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection;\n4. Patients allergic to opioids or with a history of opioid addiction and those participating in other clinical studies;\n5. Pregnant or breastfeeding women;\n6. Patients with severe organ dysfunction or failure, such as liver failure, renal failure, and respiratory failure;\n7. Patients with severe infections;\n8. Patients with severe mental illness that cannot cooperate and those taking antipsychotic drugs;\n9. Other patients considered unsuitable for this study by the researchers.",{"count":320,"type":22},166,[25],"The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia\u002Freperfusion injury in AMI patients. It will also assess the safety of injecting morphine around the stellate ganglion via ultrasound guidance. The main questions it aims to answer are:\n\n1. Does morphine regulate stellate ganglion function to reduce myocardial ischemia\u002Freperfusion injury in AMI patients?\n2. What medical problems do participants experience when receiving injected morphine around the stellate ganglion? Researchers will compare morphine to a placebo saline (as a control group) to determine whether stellate ganglion infiltration with morphine effectively treats patients with AMI following primary PCI.\n\nParticipants will:\n\n* Receive a single injection of morphine or saline around the stellate ganglion.\n* Evaluate the percentage of infarct size 7 days after surgery, or at discharge if the duration is shorter than 7 days.\n* Record their symptoms and any major adverse cardiovascular and cerebrovascular events within 30 days post-surgery.",[28],[28,325,326,327,328],"Stellate Ganglion","Percutaneous Coronary Intervention","Ischemia\u002Freperfusion injury","Morphine","2025-12-09",{"date":304,"type":33},{"date":332,"type":33},"2025-05-29",{"date":247,"type":22},{"name":335,"class":40},"The Second Hospital of Anhui Medical University",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":18,"minAge":343,"maxAge":50,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":349,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":41},"100420486","phase-4-ticagrelor-de-escalation-strategy-in-ami-patients-100420486","NCT04755387","Ticagrelor De-escalation Strategy in AMI Patients","EASTYLE (DE-escAlation Strategy for Optimal Ticagrelor Therapy in Acute MYocardiaL Infarction PatiEnts, Prospective, Multicenter, Randomized) Trial","Inclusion Criteria:\n\n* Diagnosis with acute myocardial infarction.\n* Age ≥19 year-old\n* Successful PCI with ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).\n* Provision of informed consent.\n\nExclusion Criteria:\n\n* Any prior event of hemorrhagic stroke or ICH.\n* Active bleeding (e.g., GI bleeding, ICH) or high-risk of serious bleeding.\n* Bleeding diathesis or coagulopathy (e.g., hemoglobin ≤ 10 g\u002FdL or platelet count \\\u003C 100,000\u002FμL, bleeding needing transfusion within 30 days, and so on).\n* Allergy to stent metal, contrat media, and antiplatelet regimens.\n* Moderate to severe hepatic dysfunction (Child-Pugh class B or C).\n* Need for oral anticoagulation therapy.\n* Current or potential pregnancy.\n* Currently treated with strong CYP3A4 inhibitors.\n* Life expectancy \\\u003C1 year.","19 Years",{"count":345,"type":22},2312,[54],"DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.",[28],[350,351,352,353],"Ticagrelor","DAPT","De-escalation strategy","Abbreviated strategy","2025-09-26",{"date":356,"type":33},"2025-10-01",{"date":358,"type":33},"2023-03-27",{"date":360,"type":22},"2028-01-31",{"name":362,"class":40},"Dong-A University",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":41},"100606884","effects-of-long-term-remote-ischemic-preconditioning-on-clinical-outcome-in-patients-with-acute-myocardial-infarction-100606884","NCT07181356","Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction","L-RICP-AMI","Inclusion Criteria:\n\n* Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the \"Global Unified Definition of Fourth Myocardial Infarction\"\n\nExclusion Criteria:\n\n* The patients could not tolerate RIPC or RIPerC\n* Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases\n* The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively\n* severe liver dysfunction (bilirubin \\> 20 mmol \u002F L, prothrombin time \\> 2.0 ratio)\n* Severe renal insufficiency (GFR \\\u003C 30 ml \u002F min \u002F 1.73 m2);\n* patients taking nicorandil and other drugs affecting microcirculation\n* pregnant",{"count":371,"type":22},2146,[25],"At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.",[28],"2025-09-12",{"date":377,"type":33},"2025-09-18",{"date":379,"type":33},"2025-01-01",{"date":381,"type":22},"2028-12-01",{"name":383,"class":40},"Henan Institute of Cardiovascular Epidemiology",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":391,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":400,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":41},"100366051","impact-of-treating-severe-periodontitis-on-inflammatory-activity-of-atheromatous-plaques-in-patients-with-acute-myocardial-infarction-ami-100366051","NCT04046237","Impact of Treating Severe Periodontitis on Inflammatory Activity of Atheromatous Plaques in Patients With Acute Myocardial Infarction (AMI)","PAROCARD","Inclusion Criteria:\n\n* Patients hospitalized for an acute myocardial infarction and included in the Frenchie registry\n* Score ≥ 5 on the screening questionnaire for periodontitis\n* Six teeth at least (excluding wisdom teeth)\n* Consent signature\n* Affiliation to a French medical insurance (Sécurité Sociale)\n\nExclusion Criteria:\n\n* Patients with diseases,other than cardiovascular and diabetes, known to change the periodontal state such as AIDS, rheumatoid arthritis, Chediak-Higashi syndrome, Papillon-Lefèvre\n* Systemic antibiotic therapy\\> 48 hours in the 3 months prior to inclusion\n* Acute heart failure\n* Uncontrolled ventricular rhythm disorders\n* Impossibility for the patient to attend follow-up visits\n* Impossibility to maintain the extended position for 20 minutes\n* Immunosuppressive therapy\\> 1 month in the 6 months prior to inclusion\n* Pregnancy, breastfeeding\n* Known hypersensitivity to chlorhexidine, povidone, 18-fluoro-deoxyglucose","30 Years","70 Years",{"count":394,"type":22},210,[25],"Multicenter randomized clinical trial with two arms in patients hospitalized for an AMI nested in the Frenchie registry. Periodontal therapy is performed by periodontists in the intervention group versus treatment by dental surgeons as part of their usual practice in the control group.\n\nFor the intervention group, periodontal management will be carried out for a maximum of 6 months after randomisation, prolonged by a follow-up of 6 months including a maintenance visit at M9.\n\nAll patients will have an FDG-PET at M0 and M12 for evaluation of inflammation on carotid atherosclerotic plaques.",[28,398,399],"Severe Periodontitis","Carotid Atherosclerosis",[28,398,401,399],"FDG-PET","2025-09-01",{"date":404,"type":33},"2025-09-08",{"date":406,"type":33},"2019-08-02",{"date":408,"type":22},"2028-08",{"name":410,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":435},"100505493","long-term-follow-up-in-patients-with-acute-myocardial-infarction-cohort-100505493","NCT05862103","Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort","Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort - a Prospective, Multicenter Study","Inclusion Criteria:\n\n* AMI survivors who participated in the project \"Construction and key technology research of the whole myocardial protection system for acute myocardial infarction\" and completed the 1-year visit.\n* Telephone to obtain informed consent from the subjects\u002Ffamily members of the subjects.\n\nExclusion Criteria:\n\n* Not available",{"count":419,"type":22},15000,"AMI Survivors who participated in the project \"Construction and key technology research of the whole myocardial protection system for acute myocardial infarction\" (project number 2016YFC1301100) and completed the 1-year visit were followed up by telephone at 3 years (within the corresponding follow-up time window) and 5 years after discharge to acquire the patients' medication, health status, and major adverse cardiovascular and cerebrovascular events, including death, heart failure, rehospitalization, re-myocardial infarction, revascularization, stroke, malignant arrhythmia, and bleeding events.",[28,422],"Adverse Event",[424,425,426],"Acute myocardial infarction","Major adverse cardiac and cerebrovascular event","Optimized treatment","2025-08-31",{"date":429,"type":33},"2025-09-03",{"date":431,"type":33},"2022-12-21",{"date":308,"type":22},{"name":434,"class":40},"Yu Bo",18,{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":465},"100358776","using-an-intervention-adapted-to-the-health-literacy-level-to-improve-adherence-to-medical-recommendations-100358776","NCT03951467","Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations","Impact of a Strategy Dedicated to Low Health Literacy Level Patients to Improve Their Understanding and Ownership of the Discharge Prescription in Cardio-vascular Diseases","ILIADE","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Hospitalization for at least a 2nd acute attack (systolic or diastolic)\n* Patient living at home before hospitalization for decompensation\n* Affiliated with a health insurance plan\n\nExclusion Criteria:\n\n* Short-term vital prognosis\n* Bipolar disorders, active psychoses\n* Severe dementia\n* Psychiatric or cognitive comorbidities making inclusion impossible, at the discretion of the investigator.\n* Pregnant, parturient or breastfeeding women\n* Persons deprived of liberty by a judicial or administrative decision\n* Persons admitted to a health or social establishment for purposes other than research\n* Adults subject to a legal protection measure (guardianship, curatorship)\n* Subject participating in another interventional research including an exclusion period still ongoing at inclusion\n* Score S-TOFHLA (\\>22)\n* Withdrawal of consent",{"count":445,"type":22},300,[25],"Health literacy is the ability to access, understand, evaluate and apply information in order to communicate with health professionals and understand health instructions but also, promote, maintain and improve health throughout life. Health literacy is known as a health determinant. Level of Health Literacy is low or limited within 47% of interrogated people in Europe, resulting in an inability to understand and\u002For use written texts and digital concepts about one's health.\n\nThere is a demonstrated link between low HL and low therapeutic adherence, an increase in the number of re-admissions, and more generally poor health or survival that is even more limited. An association between low LS and higher health care costs has also been reported in the USA and Switzerland. WHO highlight the central role of Health Literacyin health inequalities, regardless of the region of the world.\n\nThe investigator chose to conduct this study in patients hospitalized for an acute cardiovascular event: acute myocardial infarction or acute decompensated heart failure , as these patients have cumulative risk factors for misuse and medication errors. They are hospitalized in emergency, for shorter and shorter periods and are discharged with complex drug treatments. The data show that the return home after acute hospitalization for these conditions is a particularly high-risk period for medication errors and misuse, especially with low level of Health Literacy. The proportion of patients with preventable adverse events in the weeks following their return home ranges from 23% to 30% and nearly 60% are re-hospitalized within 6 months.\n\nThe hypothesis of the study is that in patients hospitalized for cute myocardial infarctionor acute decompensated heart failurewith low Health Literacy levels, information on discharge treatment using appropriate tools and techniques will reduce the risk of patient-related medication errors or misuse within 30 days of discharge.\n\nThe purpose of this study is to develop an educational intervention model adapted to low Health Literacy levels and routinely feasible, even in case of short stays, in complementarity with traditional therapeutic education programmes that require higher investments and are therefore not accessible to all patients. This innovative approach could then be applied to a large number of chronic diseases.",[449,28],"Acute Decompensated Heart Failure",[451,87,452,453,454,455],"Literacy","Interventional study","Randomized Controlled Trial","Tertiary prevention","Health promotion","2025-07-09",{"date":458,"type":33},"2025-07-14",{"date":460,"type":33},"2025-06-26",{"date":462,"type":22},"2027-12-26",{"name":464,"class":40},"Hospices Civils de Lyon",4,{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":475,"conditions":476,"keywords":481,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":501},"100406533","abbott-vascular-medical-device-registry-100406533","NCT04573660","Abbott Vascular Medical Device Registry","AV-MDR","Inclusion Criteria:\n\n1. Subject is at least 18 years of age.\n2. Subject has a planned procedure, or underwent a procedure, that will use\u002Fused one or more Abbott target devices covered in this registry.\n3. Subject is willing and able to comply with, or has already completed, the follow-up schedule specified in this protocol.\n4. Subject must provide written informed consent prior to any clinical investigation-related data collection or be enrolled under an IRB\u002FEC approved waiver of consent.\n\nExclusion Criteria:\n\n1\\. Subject has active symptoms and\u002For a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the prior 2 months of the date of procedure.",{"count":474,"type":22},3784,"The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.",[28,477,478,479,480],"Restenoses, Coronary","Coronary Artery Lesions","Venous Embolism","Arterial Embolism",[482,483,484,485,486,487,488,489,490,491],"Coronary and peripheral stents","ABT-CIP-10349","Vascular plugs","Pacing catheters","Measurement and imaging (FFR and OCT)","Peripheral dilatation catheters","Coronary dilatation catheters","Coronary and peripheral guidewires","Vessel closure\u002Fcompression devices","Vascular access introducers","2025-07-01",{"date":494,"type":33},"2025-07-03",{"date":496,"type":33},"2020-10-25",{"date":498,"type":22},"2031-11",{"name":500,"class":269},"Abbott Medical Devices",37,{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":526},"100555718","phase-4-treatment-with-apixaban-versus-warfarin-in-patients-with-left-ventricular-thrombus-after-acute-myocardial-infarction-100555718","NCT06515730","Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","RandomizEd compariSOn of Apixaban Versus Warfarin in Patients With Left VEntricular Thrombus After Acute Myocardial Infarction (RESOLVE-AMI)","RESOLVE-AMI","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of signing the informed consent\n* LV thrombus confirmed on TTE\\* day 1-28 after the AMI\n* Signed informed consent\n* Criteria applicable only for female subjects: Women of childbearing potential must provide a negative pregnancy test not be breastfeeding and be willing and able to use highly effective contraception. Women of non-childbearing potential must be 1 year post-menopausal.\n\nExclusion Criteria:\n\n* Ongoing\\* treatment with anticoagulant therapy due to Mechanical heart valve prosthesis Atrial fibrillation with or without significant mitral valve stenosis Venous thromboembolism requiring anticoagulant therapy Thrombophilia requiring anticoagulant therapy Preexisting LV thrombus already treated with anticoagulant therapy Other reasons for anticoagulant therapy\n* High bleeding risk Active non-trivial bleeding Known chronic bleeding disorder Severe anemia defined as hemoglobin \\\u003C 80g\u002FL Thrombocytopenia defined as platelet count \\\u003C 80 x 10\\^9\n* Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or known hepatic insufficiency classified as Child-Pugh C or D at randomization\n* Known allergy, intolerance or hypersensitivity to either of the study interventions\n* Any contraindication for the use of an anticoagulant or listed in the local labelling for apixaban or warfarin.\n* Participation in other study investigating effects and safety of anticoagulant treatment.\n* Known current alcohol or drug abuse\n* Any other condition, as judged by the investigator, that would make the participant unsafe or unsuitable for the study or life expectancy \\\u003C 6 months",{"count":511,"type":22},212,[54],"The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.",[515,28],"Left Ventricular Thrombus",[517,518],"Apixaban","warfarin",{"date":492,"type":33},{"date":521,"type":33},"2025-04-08",{"date":523,"type":22},"2028-07-01",{"name":525,"class":40},"Karolinska Institutet",16,{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":539,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":41},"100431545","phase-4-peri-treatment-of-sglt-2-inhibitor-on-myocardial-infarct-size-and-remodeling-index-in-patients-with-acute-myocardial-infarction-and-high-risk-of-heart-failure-undergoing-percutaneous-coronary-intervention-100431545","NCT04899479","Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention","Peri-tREatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index Measured by Cardiac maGnetic rEsonance Imaging in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention","PRESTIGE-AMI","Inclusion Criteria:\n\n* 1\\) Subject must be at least 18 years of age 2) Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving SGLT-2 inhibitor and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure 3) Diagnosis of Type 1 myocardial infarction (MI) (ST-segment elevation MI \\[STEMI\\] or Non-ST-segment elevation MI \\[NSTEMI\\]) i) Detection of a rise and\u002For fall of cardiac troponin values with at least 1 value above the 99th percentile upper reference limit ii) Symptoms or electrocardiographic changes suggesting myocardial ischemia 4) High risk of heart failure (at least one of the two criteria below are met) i) Left ventricular ejection fraction \\\u003C 50% ii) Symptoms or signs of pulmonary congestion requiring treatment\n\nExclusion Criteria:\n\n* 1\\) Target lesion is not suitable for PCI by operator's decision 2) Patients requiring cardiopulmonary resuscitation due to cardiac arrest before randomization 3) Rescue PCI after thrombolysis or facilitated PCI 4) Previous MI 5) Previous history of heart failure 6) Patients who have been taking SGLT-2 inhibitor 7) Patients with glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m2 or on dialysis 8) Type 1 diabetes mellitus (DM) 9) Known hypersensitivity or contraindications to study medications (SGLT-2 inhibitor) 10) Pregnant or lactating women 11) Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)",{"count":21,"type":22},[54],"We aimed to identify whether SGLT-2 inhibitor administration before and after coronary intervention is effective in reducing the size of infarction and myocardial remodeling in patients with acute myocardial infarction (AMI) and high risk of heart failure, and its mechanism. For this reason, we compared cardiac magnetic resonance imaging (CMR) parameters and clinical outcomes between the SGLT-2 inhibitor group and the control group to confirm the efficacy and safety of SGLT-2 inhibitors.",[28,301],[326,540,541],"Infarct size","Cardiac Magnetic Resonance Imaging","2025-06-22",{"date":460,"type":33},{"date":545,"type":33},"2021-07-05",{"date":306,"type":22},{"name":249,"class":40},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":41},"100366414","french-cohort-of-myocardial-infarction-evaluation-100366414","NCT04050956","French Cohort of Myocardial Infarction Evaluation","FRENCHIE","Inclusion Criteria:\n\n* Myocardial infarction (MI) within 48h of symptom onset, characterized by the typical increased or fall of troponin (or CPKMB) associated with at least one of the following elements :\n* Symptoms compatible with myocardial ischemia\n* Appearance of pathological Q waves\n* ST- T changes compatible with myocardial ischemia (ST segment elevation or depression, T-wave inversion)\n* Written consent.\n* Covered by French medical insurance (\"Sécurité Sociale\")\n\nExclusion Criteria:\n\n* Iatrogenic MI defined as MI occurring within 48h of a therapeutic procedure\n* AMI diagnosis invalidated in favor of another diagnosis",{"count":556,"type":22},30000,"Over the last two decades, considerable progress has been made in the management of Acute Myocardial Infarction (AMI), both in the acute phase and in monitoring beyond the hospital phase. Nevertheless, the evolution of care practices and their impact on the mid- and long-term prognosis of patients admitted to the intensive care unit for acute myocardial infarction remain relatively little studied exhaustively.\n\nThe aim of this study is to assess the profile of AMI patients, their management and follow-up in order to evaluate the relationship between these factors and outcomes.",[28],[28,560,561,562,563],"Registry","Outcomes","Medico-economic evaluation","Comorbidities","2025-06-20",{"date":566,"type":33},"2025-06-25",{"date":568,"type":33},"2019-03-11",{"date":570,"type":22},"2049-03-22",{"name":410,"class":40},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":603},"100493146","physiology-guided-vs-angiography-guided-non-culprit-lesion-complete-revascularization-for-acute-mi--multivessel-disease-100493146","NCT05701358","Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease","A Randomized Trial of Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization Strategies & an Observational Study of Optical Coherence Tomography in Patients With Acute MI & Multivessel Coronary Artery Disease","COMPLETE-2","Inclusion Criteria:\n\n1. Patients presenting with STEMI or type 1 NSTEMI and within 72 hours of successful culprit-lesion PCI\n2. Residual coronary artery disease defined as at least 1 additional non-infarct-related coronary artery stenosis that meets all of the following criteria:\n\n   1. Amenable to successful treatment with PCI\n   2. At least 50% diameter stenosis by visual estimation\n   3. At least 2.5 mm in diameter\n3. Planned complete revascularization strategy for qualifying MI\n\nExclusion Criteria:\n\n1. Planned or prior coronary artery bypass graft (CABG) surgery\n2. Inability to clearly identify a culprit lesion for STEMI or NSTEMI based on angiographic appearance and\u002For ECG changes and\u002For regional wall motion abnormalities\n3. Prior PCI of a non-culprit lesion in a different vessel from the culprit lesion within 45 days of randomization\n4. Planned medical treatment of all qualifying non-culprit lesions (i.e., no PCI)\n5. Presence of severe non-culprit-lesion stenosis with reduced epicardial flow (TIMI flow ≤ 2) or \\>90% visual diameter stenosis\n6. Presence of a chronic total occlusion (CTO) if it is the only qualifying non-culprit lesion (patients with a CTO plus additional qualifying non-culprit lesions are eligible)\n7. The only qualifying non-culprit lesion is in the same vessel territory as the culprit lesion\n8. Baseline STEMI or NSTEMI was due to a suspected non-atherothrombotic mechanism such as type 2 MI (supply-demand mismatch), including spontaneous coronary artery dissection or coronary artery embolism\n9. Non-cardiovascular co-morbidity with expected life expectancy \\\u003C2 years\n10. Any other medical, geographic, or social factor making study participation impractical or precluding 5 year follow-up",{"count":581,"type":22},5100,[25],"COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI).\n\nCOMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.",[28,585],"Coronary Artery Disease",[587,588,589,590,591,592,593],"NSTEMI","STEMI","multi-vessel disease","optical coherence tomography","FFR","RFR","percutaneous coronary intervention","2025-06-16",{"date":596,"type":33},"2025-06-19",{"date":598,"type":33},"2023-06-22",{"date":600,"type":22},"2028-06",{"name":602,"class":40},"Population Health Research Institute",113,{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":611,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":620,"locationsCount":41},"100592597","wearable-devices-faciliate-the-management-of-ami-patients-100592597","NCT06995495","Wearable Devices Faciliate the Management of AMI Patients","Wearable Device for Characterizing AMI Patients After Primary PCI and Predicting the Clinical Outcomes","Inclusion Criteria:\n\n* Aged 18-75 years old\n* Diagnosed with STEMI or NSTEMI (ACC\u002FAHA guidelines)\n* Half male and half female\n* Undergo CAG and PCI treatment;\n* Written informed consent.\n\nExclusion Criteria:\n\n* People under the age of 18 years old;\n* Patients who are pregnant\u002Fbreastfeeding;\n* Patients who are allergic to the metallic or plastic components of the wearable devices",{"count":612,"type":22},400,"The study will explore the use of wearable technology to consistently monitor patients with acute myocardial infarction (AMI) receiving primary percutaneous coronary intervention (PCI). Parameters such as heart rate, sleep time, physical activity, and blood pressure will be collected and analyzed to characterize the patients and predict clinical outcomes.",[28],"2025-05-20",{"date":332,"type":33},{"date":618,"type":33},"2024-04-01",{"date":356,"type":22},{"name":310,"class":40},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":628,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":636,"leadSponsor":638,"locationsCount":41},"100592499","fibrosis-assessment-in-myocardial-infarction-associated-ventricular-aneurysm-100592499","NCT06994221","Fibrosis Assessment in Myocardial Infarction-associated Ventricular Aneurysm","Assessment of Myocardial Fibrosis by 18F-FAPI\u002FPET-CT in Patients With Myocardial Infarction-associated Ventricular Aneurysm","Inclusion Criteria:\n\n* Aged 18-75 years old\n* Diagnosed with STEMI or NSTEMI (ACC\u002FAHA guidelines)\n* Half male and half female\n* Undergo CAG and PCI treatment;\n* Receive either echocardiography or CMR to identify a ventricular aneurysm;\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients under the age of 18 years old;\n* Patients who are pregnant\u002Fbreastfeeding;\n* Patients who has a previous history of allergy to radio tracers.",{"count":629,"type":22},20,"The study will use 18F-FAPI PET\u002FCT to study myocardial fibrosis in patients diagnosed with myocardial infarction-associated ventricular aneurysm (MI-VA). Participants will receive the PET\u002FCT scan during hospital stay, as well as serial echocardiography and telephonic follow-ups. Analysed will focus on the characterization of myocardial fibrosis and its correlations with the clinical prognosis in the patients.",[28,632,633],"Ventricular Aneurysm Following Acute Myocardial Infarction","Myocardial Fibrosis",{"date":332,"type":33},{"date":219,"type":33},{"date":637,"type":22},"2025-12-31",{"name":310,"class":40},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":651,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":661,"locationsCount":73},"100581762","assessing-coronary-non-culprit-plaque-early-with-start-of-pcsk9-inhibitors-in-acute-myocardial-infarction-access-ami-100581762","NCT06854523","Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)","Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction","ACCESS-AMI","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Admitted to hospital for acute myocardial infarction (STEMI, NSTEMI) and successfully underwent PCI of the infarct vessel.\n3. Coronary angiography revealed two non-infarct-related arteries with non-blocking lesions (diameter stenosis of 40-70%).\n4. Able to sign informed consent.\n5. Willing to undergo 1-year follow-up.\n\nExclusion Criteria:\n\n1. Left main artery disease or severe coronary artery calcification;\n2. Hemodynamic instability or uncontrolled arrhythmia;\n3. History of coronary artery bypass;\n4. severe renal insufficiency, active liver disease or liver insufficiency, hematological disease, metabolic or endocrine dysfunction, systemic infection, active malignant tumor and other potentially life-threatening diseases, or the expected survival time is \\\u003C 1 year;\n5. Received any PCSK9 inhibitor treatment within the previous 3 months;\n6. Pregnant or nursing women or women planning pregnancy;\n7. The researcher determined that it was not suitable for inclusion in the group.",{"count":445,"type":22},[25],"This study is planned to start on January 2024.\n\nThe goal of this clinical trial is to learn whether the perioperative administration (within 24 hours before or after primary PCI) of PCSK9 inhibitors can ameliorate plaque progression and adverse outcomes in patients with acute myocardial infarction (AMI). The main questions it aims to answer are:\n\nCan perioperative PCSK9 inhibition improve the plaque stability and inflammation of perivascular adipose tissue (index of plaque attenuation（IPA ）and perivascular fat attenuation index（FAI）) of non-target lesions? Researchers will compare PCSK9 inhibitors with statin plus ezetimibe therapy to evaluate the potential of PCSK9 inhibitors in mitigating the progression of non-target lesion plaques and reducing adverse cardiovascular events in patients with AMI.\n\nParticipants will:\n\nTake PCSK9 inhibitors every two weeks or daily statin plus ezetimibe therapy. Conduct a follow-up examination with optical coherence tomography (OCT) or coronary computed tomography angiography (CTA) after 12 months.\n\nRecord the occurrence of major adverse cardiovascular events.",[28],[28,652,653,654],"Pericoronary artery fat attenuation index","Index of Plaque Attenuation","PCSK9 Inhibitor","2025-02-25",{"date":657,"type":33},"2025-03-03",{"date":659,"type":22},"2025-04-15",{"date":70,"type":22},{"name":662,"class":40},"Yun Dai Chen"]